Gender Male
LinkedIn View on LinkedIn
Christopher Trummer is a TechBio founder, operator, and investor. He is CEO and Co-Founder of pixlbio, the predictive biology company formed from the merger of DefiniGEN and Phenaros in 2025. Before pixlbio, Christopher founded Celeris Therapeutics, an AI-first protein degrader company, and served as CEO — raising ~€20M in committed VC capital,
winning a competitive EIC Accelerator grant, and building partnerships with major pharma. Under his leadership, CelerisTx was admitted to Y Combinator and later StartX. He led the acquisition of DefiniGEN into Phenaros, creating pixlbio. Christopher previously served on the board of the Austrian Biotech Association and selectively backs exceptional founders at the earliest stages.
